The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

134 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

48-week open label randomized phase IV investigator initiated intervention study. The purpose of this study is to evaluate whether HIV-1 suppression can be maintained by DTG monotherapy in HIV-1 infected, virologically suppressed patients on cART.

104 adults fulfilling the in and exclusion criteria and on stable cART will be randomized over 2 investigational arms.

The first arm will contain the direct switch population. This population will switch directly from stable cART to Dolutegravir mono-therapy on baseline visit.

The second arm will contain the delayed-switch population. This group will switch from stable cART to Dolutegravir monotherapy 24 weeks after baseline visit.

The main goal is to investigate if Dolutegravir mono-therapy could be non-inferior to cART in virological suppressed HIV-1 infected adults.

If a interim analysis (performed when 40 patients on dolutegravir monotherapy have passed week 12) shows that it is safe to continue the study, an additional 30 patients will be included on top of the 104 patients needed for the primary endpoint analysis. In contrast to the primary endpoint population, these additional 30 patients will have a CD4 nadir \<200 but a CD4 \>350 at the time of the screening visit. Besides that, these 30 patients will have to fulfill all other in and exclusion criteria of the primary endpoint population (specifically a viral load never \>100.000). These 30 patients are part of a pilot study looking at the possibility to broaden the eligible population in a future larger randomized clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

NCT02227238

HIV Infections

COMPLETED PHASE3

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

NCT03198884

HIV-1-infection

COMPLETED

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

NCT03813979

HIV-1-infection Hepatic Impairment

WITHDRAWN PHASE4

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

NCT03991013

HIV Infections

COMPLETED PHASE2

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir

NCT00458302

HIV Infections AIDS Virus Human Immunodeficiency Virus +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DTG Monotherapy will be considered non-inferior to cART if the lower bound of the one sided 97.5%CI for the difference in proportion of patients reaching the primary endpoint is not lower than -12%. For this purpose, a sample size of 52 per arm would provide 80% power at alpha 0.025 to establish non-inferiority of DTG monotherapy compared with cART when the primary endpoint success rate is 95% in both treatment arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A - Direct Switch

Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks

Group Type EXPERIMENTAL

Dolutegravir

Intervention Type DRUG

Switch from combination antiretroviral therapy to dolutegravir monotherapy

Group B - Delayed Switch

Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks

Group Type EXPERIMENTAL

Dolutegravir

Intervention Type DRUG

Switch from combination antiretroviral therapy to dolutegravir monotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dolutegravir

Switch from combination antiretroviral therapy to dolutegravir monotherapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tivicay S/GSK1349572

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented HIV-1 positive by ELISA or Western Blot or Plasma HIV-RNA \>1000 c/ml.
* 18 years or older.
* HIV-RNA ≤50 copies/mL for ≥24 weeks.
* Historical baseline HIV-RNA plasma load \<100.000 c/ml
* CD4 count nadir pre-cART ≥200 cells/mm3
* Not on strong UGT1A1 or CYP3A4 inducing agents as stated in DTG SPC.
* General medical condition does not interfere with trial procedures (on investigators' discretion)
* Females should have no plans of becoming pregnant during the next 18 months after the baseline visit
* Females are eligible if:

1. They do not plan to become pregnant during the study
2. Negative screening pregnancy test and uses one of the following methods: 1.Abstinence from penile/vaginal intercourse during the study; 2.Double barrier contraceptive methods 1 of which must be condom.

Exclusion Criteria

* Previous virological failure on any ART.
* Patient without documented anti-HBs antibodies.
* Subjects positive for hepatitis B at screening (HBsAg+).
* Any documented genotypic HIV-1 resistance with at least low-level resistance according to stanford HIV drug resistance database
* No record of the historical baseline plasma viral load available
* Subjects with concomitant CDC-C opportunistic infections within 90 days of screening.
* Subjects with history of allergy to INI.
* Subjects with creatinine clearance \<50mL/min according to CKD-EPI.
* Subjects with hepatic impairment of at least Child-Pugh B.
* Exposure to experimental drug or experimental HIV-1 vaccine within 90 days of start of DTG.
* Screening ALT \>5x ULN or ALT\>3xULN and bilirubin \>2 ULN.
* Patient (man or woman) planning or hoping to conceive a child/become pregnant during the study
* Patients who cannot take DTG 2 hours before or 6 hours after antacids, calciumcarbonate or iron supplements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No